{
  "symbol": "JNJ",
  "year": 2025,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.178,
    "forward_ratio": 0.0,
    "hedge_ratio": 0.684
  },
  "top_positive": [
    {
      "sent": "Risks and uncertainties include, but are not limited to: Risks related to product development, market success and competition \u2022 Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company\u2019s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; \u2022 Challenges to the Company\u2019s ability to secure and maintain adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets; \u2022 The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses; \u2022 Increasingly aggressive and frequent challenges to the Company\u2019s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected; \u2022 Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence; \u2022 Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies; \u2022 Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors;\u00a0and \u2022 Allegations that the Company\u2019s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company\u2019s ability to sell the products in question and require the payment of money damages and future royalties.",
      "score": 0.9961
    },
    {
      "sent": "Tabl e of Contents Part I \u2014 Financial information Item 1 \u2014 Financial statements Johnson & Johnson and subsidiaries consolidated balance sheets (Unaudited; Dollars in Millions Except Share and Per Share Data) March 30, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 38,474 24,105 Marketable securities 307 417 Accounts receivable, trade, less allowances $ 170 (2024, $ 167 ) 16,020 14,842 Inventories (Note 2) 12,659 12,444 Prepaid expenses and other 4,091 4,085 Total current assets 71,551 55,893 Property, plant and equipment at cost 49,884 48,768 Less: accumulated depreciation ( 29,013 ) ( 28,250 ) Property, plant and equipment, net 20,871 20,518 Intangible assets, net (Note 3) 36,755 37,618 Goodwill (Note 3) 44,468 44,200 Deferred taxes on income (Note 5) 8,492 10,461 Other assets 11,534 11,414 Total assets $ 193,671 180,104 Liabilities and shareholders\u2019 equity Current liabilities: Loans and notes payable $ 13,897 5,983 Accounts payable 9,545 10,311 Accrued liabilities 7,913 8,549 Accrued rebates, returns and promotions 18,780 17,580 Accrued compensation and employee related obligations 2,551 4,126 Accrued taxes on income (Note 5) 4,217 3,772 Total current liabilities 56,903 50,321 Long-term debt (Note 4) 38,355 30,651 Deferred taxes on income (Note 5) 2,428 2,448 Employee related obligations (Note 6) 7,046 7,255 Long-term taxes payable (Note 5) 395 390 Other liabilities 10,435 17,549 Total liabilities $ 115,562 108,614 Commitments and Contingencies (Note 11) Shareholders\u2019 equity: Common stock \u2014 par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 11,740 ) ( 11,741 ) Retained earnings and Additional paid-in capital 162,635 155,791 Less: common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares) 75,906 75,680 Total shareholders\u2019 equity $ 78,109 71,490 Total liabilities and shareholders\u2019 equity $ 193,671 180,104 See Notes to Consolidated Financial Statements Form 10-Q 1 Tabl e of Contents Johnson & Johnson and subsidiaries consolidated statements of earnings (Unaudited; Dollars & Shares in Millions Except Per Share Amounts) Fiscal First Quarter Ended March 30, 2025 Percent to Sales March 31, 2024 Percent to Sales Sales to customers (Note 9) $ 21,893 100.0 % $ 21,383 100.0 % Cost of products sold 7,357 33.6 6,511 30.4 Gross profit 14,536 66.4 14,872 69.6 Selling, marketing and administrative expenses 5,112 23.3 5,257 24.6 Research and development expense 3,225 14.7 3,542 16.6 Interest income ( 332 ) ( 1.5 ) ( 364 ) ( 1.7 ) Interest expense, net of portion capitalized 204 0.9 155 0.7 Other (income) expense, net ( 7,321 ) ( 33.4 ) 2,404 11.2 Restructuring (Note 12) 17 0.1 164 0.8 Earnings before provision for taxes on income 13,631 62.3 3,714 17.4 Provision for taxes on income (Note\u00a05) 2,632 12.1 459 2.2 Net earnings $ 10,999 50.2 % $ 3,255 15.2 % Net earnings per share (Note 8) Basic $ 4.57 $ 1.35 Diluted $ 4.54 $ 1.34 Avg.",
      "score": 0.9726
    },
    {
      "sent": "Risks related to the Company\u2019s strategic initiatives and healthcare market trends \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; and \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.",
      "score": 0.8625
    }
  ],
  "top_negative": [
    {
      "sent": "Risks related to economic conditions, financial markets and operating internationally \u2022 The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates; \u2022 The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins; \u2022 Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation, and the impact of such changes on raw material prices, supply chains market volatility and the pace of product development; \u2022 The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal\u00a0systems; \u2022 The impact of global public health crises and pandemics; \u2022 Changes to global climate, extreme weather and natural disasters that could affect demand for the Company\u2019s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company\u2019s products and operations; \u2022 The impact of global or economic changes or events, including global tensions and war; and \u2022 The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.",
      "score": -0.9531
    },
    {
      "sent": "Risks related to supply chain and operations \u2022 Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action; \u2022 Interruptions and breaches of the Company\u2019s information technology systems or those of the Company\u2019s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; \u2022 Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company\u2019s products; and \u2022 The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.",
      "score": -0.765
    },
    {
      "sent": "Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company\u2019s control.",
      "score": -0.7184
    }
  ],
  "forward_snippets": [],
  "curated_text": "Symbol: JNJ. Year: 2025. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Risks and uncertainties include, but are not limited to: Risks related to product development, market success and competition \u2022 Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company\u2019s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; \u2022 Challenges to the Company\u2019s ability to secure and maintain adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets; \u2022 The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses; \u2022 Increasingly aggressive and frequent challenges to the Company\u2019s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected; \u2022 Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence; \u2022 Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies; \u2022 Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors;\u00a0and \u2022 Allegations that the Company\u2019s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company\u2019s ability to sell the products in question and require the payment of money damages and future royalties. Tabl e of Contents Part I \u2014 Financial information Item 1 \u2014 Financial statements Johnson & Johnson and subsidiaries consolidated balance sheets (Unaudited; Dollars in Millions Except Share and Per Share Data) March 30, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents (Note 4) $ 38,474 24,105 Marketable securities 307 417 Accounts receivable, trade, less allowances $ 170 (2024, $ 167 ) 16,020 14,842 Inventories (Note 2) 12,659 12,444 Prepaid expenses and other 4,091 4,085 Total current assets 71,551 55,893 Property, plant and equipment at cost 49,884 48,768 Less: accumulated depreciation ( 29,013 ) ( 28,250 ) Property, plant and equipment, net 20,871 20,518 Intangible assets, net (Note 3) 36,755 37,618 Goodwill (Note 3) 44,468 44,200 Deferred taxes on income (Note 5) 8,492 10,461 Other assets 11,534 11,414 Total assets $ 193,671 180,104 Liabilities and shareholders\u2019 equity Current liabilities: Loans and notes payable $ 13,897 5,983 Accounts payable 9,545 10,311 Accrued liabilities 7,913 8,549 Accrued rebates, returns and promotions 18,780 17,580 Accrued compensation and employee related obligations 2,551 4,126 Accrued taxes on income (Note 5) 4,217 3,772 Total current liabilities 56,903 50,321 Long-term debt (Note 4) 38,355 30,651 Deferred taxes on income (Note 5) 2,428 2,448 Employee related obligations (Note 6) 7,046 7,255 Long-term taxes payable (Note 5) 395 390 Other liabilities 10,435 17,549 Total liabilities $ 115,562 108,614 Commitments and Contingencies (Note 11) Shareholders\u2019 equity: Common stock \u2014 par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 11,740 ) ( 11,741 ) Retained earnings and Additional paid-in capital 162,635 155,791 Less: common stock held in treasury, at cost ( 714,218,000 and 712,921,000 shares) 75,906 75,680 Total shareholders\u2019 equity $ 78,109 71,490 Total liabilities and shareholders\u2019 equity $ 193,671 180,104 See Notes to Consolidated Financial Statements Form 10-Q 1 Tabl e of Contents Johnson & Johnson and subsidiaries consolidated statements of earnings (Unaudited; Dollars & Shares in Millions Except Per Share Amounts) Fiscal First Quarter Ended March 30, 2025 Percent to Sales March 31, 2024 Percent to Sales Sales to customers (Note 9) $ 21,893 100.0 % $ 21,383 100.0 % Cost of products sold 7,357 33.6 6,511 30.4 Gross profit 14,536 66.4 14,872 69.6 Selling, marketing and administrative expenses 5,112 23.3 5,257 24.6 Research and development expense 3,225 14.7 3,542 16.6 Interest income ( 332 ) ( 1.5 ) ( 364 ) ( 1.7 ) Interest expense, net of portion capitalized 204 0.9 155 0.7 Other (income) expense, net ( 7,321 ) ( 33.4 ) 2,404 11.2 Restructuring (Note 12) 17 0.1 164 0.8 Earnings before provision for taxes on income 13,631 62.3 3,714 17.4 Provision for taxes on income (Note\u00a05) 2,632 12.1 459 2.2 Net earnings $ 10,999 50.2 % $ 3,255 15.2 % Net earnings per share (Note 8) Basic $ 4.57 $ 1.35 Diluted $ 4.54 $ 1.34 Avg. Risks related to the Company\u2019s strategic initiatives and healthcare market trends \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; and \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected. Top negative sentences: Risks related to economic conditions, financial markets and operating internationally \u2022 The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates; \u2022 The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins; \u2022 Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation, and the impact of such changes on raw material prices, supply chains market volatility and the pace of product development; \u2022 The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal\u00a0systems; \u2022 The impact of global public health crises and pandemics; \u2022 Changes to global climate, extreme weather and natural disasters that could affect demand for the Company\u2019s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company\u2019s products and operations; \u2022 The impact of global or economic changes or events, including global tensions and war; and \u2022 The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets. Risks related to supply chain and operations \u2022 Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action; \u2022 Interruptions and breaches of the Company\u2019s information technology systems or those of the Company\u2019s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; \u2022 Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company\u2019s products; and \u2022 The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company\u2019s control. Forward-looking snippets: "
}